Results 101 to 110 of about 15,205 (209)

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, EarlyView.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

Novel Isocratic HPLC Method for Simultaneous Estimation of Sacubitril and Valsartan in Bulk and Formulation [PDF]

Brazilian Archives of Biology and Technology
In compliance with ICH requirements, a new selective, precise, and accurate reverse-phase High-Performance Liquid Chromatographic method for valsartan and sacubitril quantification was developed and validated. Eluents were detected at 284 nm.
Harshavardhan Rajendra Karnik, Ambar Bhikasaheb Marne, Ashwin Bhanudas Kuchekar, Ashwini Ramkrishna Gawade   +3 more
doaj   +1 more source

Sacubitril/valsartan improved microvascular endothelial function in a young patient with COVID-19-related mild left ventricular dysfunction

, 2022
Marcin Hellmann, Edyta Dąbrowska, Marta Żarczyńska-Buchowiecka, Marzena Romanowska-Kocejko, Krzysztof Narkiewicz, Marcin Gruchała, Maria Dudziak   +6 more
openalex   +2 more sources

Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
Sacubitril/Valsartan (Sac/Val) alleviates fibrosis and inflammation in metabolic dysfunction‐associated steatohepatitis (MASH). Its anti‐fibrotic effect is linked to the suppression of Integrin alpha 8 (Itga8), a protein crucial for hepatic stellate cell (HSC) activation and collagen production.
Hayato Kawamura, Aya Naiki‐Ito, Xiaochen Kuang, Akihiro Murakami, Masayuki Komura, Takanori Suzuki, Hiroyuki Kato, Yuko Nagayasu, Kentaro Matsuura, Kei Fujiwara, Hiromi Kataoka, Satoru Takahashi   +11 more
wiley   +1 more source

Detection of muscular system adverse reaction signals in sacubitril/valsartan treatment combined with statins

Frontiers in Pharmacology
ObjectiveTo detect muscular system adverse reaction signals of sacubitril/valsartan treatment combined with statins (atorvastatin, rosuvastatin, simvastatin) to provide a reference for clinical administration.MethodsMultiplicative and additive models ...
Fukun Zhao, Min Luo, Yuanmin Wang, Mu Su, Fei Tang   +4 more
doaj   +1 more source

Establishment of a mouse model for ischaemic heart failure induced by coronary microembolization via left ventricular oil injection

Experimental Physiology, EarlyView.
Abstract Over the past three decades, there has been a steady increase in clinical attention to ischaemic heart failure caused by coronary microembolization. Nonetheless, a suitable mouse model for studying this condition remains limited. In the present study, we developed a mouse model of coronary microembolization‐induced ischaemic heart failure by ...
Lang Pei, Yusheng Hong, Qiuyue Wu, Jianyi Lv, Changlong Li, Xueyun Huo, Xin Liu, Di Zhang, Meng Guo, Zhenwen Chen, Xiaoyan Du   +10 more
wiley   +1 more source

Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control

, 2022
Karishma Mahtani, Brihitejas Patel, Brian Wang, Anthony Barron   +3 more
openalex   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Takotsubo Cardiomyopathy Secondary to Lung Transplantation Followed by Reduced Ejection Fraction Heart Failure: A Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
A 23‐year‐old male with cystic fibrosis developed Takotsubo cardiomyopathy with left ventricular reduced ejection fraction during bilateral lung transplantation. One year later, he presented with reduced left ventricular ejection fraction and pulmonary edema in the context of medication non‐adherence.
Azadeh Moradkhani, Masoume Avateffazeli, Farah Naghashzadeh, Salman Soleimani, Zargham Hossein Ahmadi, Alireza Jahangiri Fard, Sina Homaee, Mohammad Varahram, Mahshid Hajiali, Shadi Shafaghi, Atefeh Abedini   +10 more
wiley   +1 more source